437,051 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Sutro Biopharma, Inc. (NASDAQ:STRO) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 437,051 shares of the company’s stock, valued at approximately $1,512,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Gladius Capital Management LP acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at approximately $28,000. ProShare Advisors LLC increased its stake in Sutro Biopharma by 49.1% in the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after acquiring an additional 5,373 shares during the last quarter. Lazard Asset Management LLC bought a new position in Sutro Biopharma in the first quarter valued at approximately $92,000. The Manufacturers Life Insurance Company lifted its stake in Sutro Biopharma by 27.4% during the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after purchasing an additional 7,082 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Sutro Biopharma by 24.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after purchasing an additional 3,578 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Analyst Ratings Changes

STRO has been the subject of a number of research analyst reports. Truist Financial lowered their price target on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price target on shares of Sutro Biopharma in a report on Friday, October 11th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Sutro Biopharma presently has an average rating of “Buy” and an average target price of $12.14.

Sutro Biopharma Price Performance

NASDAQ STRO opened at $2.60 on Wednesday. The stock has a market capitalization of $214.40 million, a P/E ratio of -1.62 and a beta of 1.17. The business has a 50 day simple moving average of $3.54 and a 200 day simple moving average of $3.77. Sutro Biopharma, Inc. has a one year low of $2.13 and a one year high of $6.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.